Living Cell Technologies Ltd
ASX:LCT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
JSW Steel Ltd
NSE:JSWSTEEL
|
IN |
Living Cell Technologies Ltd
Other Current Assets
Living Cell Technologies Ltd
Other Current Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Living Cell Technologies Ltd
ASX:LCT
|
Other Current Assets
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Mesoblast Ltd
ASX:MSB
|
Other Current Assets
$7.9m
|
CAGR 3-Years
11%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
7%
|
|
|
CSL Ltd
ASX:CSL
|
Other Current Assets
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Race Oncology Ltd
ASX:RAC
|
Other Current Assets
AU$255.3k
|
CAGR 3-Years
-26%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Other Current Assets
AU$16.1m
|
CAGR 3-Years
21%
|
CAGR 5-Years
43%
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Other Current Assets
AU$460.9k
|
CAGR 3-Years
19%
|
CAGR 5-Years
25%
|
CAGR 10-Years
N/A
|
|
Living Cell Technologies Ltd
Glance View
Living Cell Technologies Ltd. is a biotechnology company, which engages in the development of treatments for implanting healthy living cells to replace or repair diseased or damaged organs for life threatening diseases. The company is headquartered in Melbourne, Victoria. The company went IPO on 2004-09-01. The firm is focused on discovering and developing treatments for conditions, such as Parkinson's disease, diabetes, obesity and migraine. The firm's product pipeline consists of LP-003 for anti-obesity, LC-002 for migraine treatment and NTCELL for Parkinson's disease. Its Long-acting Pramlintide, LP-003 is a peptide drug that reduces caloric intake targeting obesity and it is also used for the treatment of diabetes. LC-002, is a receptor blocker targeting calcitonin gene-related peptide (CGRP), a neuropeptide hormone found in the nervous system. NTCELL is an alginate coated capsule containing clusters of neonatal porcine choroid plexus cells targeting Parkinson's disease. NTCELL's choroid plexus cells are coated with LCT's IMMUPEL technology to protect them from attack by the immune system. The company has completed Phase I/IIa clinical trial and phase IIb trials for mid- to late-stage Parkinson's disease.
